intetumumab (CNTO 95) / J&J  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
intetumumab (CNTO 95) / J&J
NCT00537381 / 2006-005766-39: An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer

Completed
2
131
US, Europe, RoW
Docetaxel, Prednisone, Intetumumab, CNTO 95, Placebo
Centocor, Inc.
Prostatic Neoplasms
11/09
11/09
NCT00246012 / 2004-002130-18: A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Completed
1/2
144
US, Europe
Intetumumab, Dacarbazine, Placebo
Centocor, Inc., Janssen-Cilag Farmaceutica, S.R.L.
Melanoma
06/08
02/09

Download Options